Entacapone

Identification

Summary

Entacapone is a selective reversible catechol-O-methyltransferase inhibitor for the treatment of Parkinson's disease.

Brand Names
Comtan, Comtess, Stalevo
Generic Name
Entacapone
DrugBank Accession Number
DB00494
Background

Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 305.286
Monoisotopic: 305.101170605
Chemical Formula
C14H15N3O5
Synonyms
  • (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
  • Entacapona
  • Entacapone
  • Entacaponum
  • N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
External IDs
  • OR 611
  • OR-611

Pharmacology

Indication

Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to manageParkinson's disease (pd)Combination Product in combination with: Levodopa (DB01235), Carbidopa (DB00190)••••••••••••••••••
Used as adjunct in combination to treatWearing off effectRegimen in combination with: Carbidopa (DB00190), Levodopa (DB01235)••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Entacapone is structurally and pharmacologically related to tolcapone, but unlike tolcapone, is not associated with hepatotoxicity. Entacapone is used in the treatment of Parkinson’s disease as an adjunct to levodopa/carbidopa therapy. Entacapone selectively and reversiblly inhibits catechol-O-methyltransferase (COMT). In mammals, COMT is distributed throughout various organs with the highest activities in the liver and kidney. COMT also occurs in the heart, lung, smooth and skeletal muscles, intestinal tract, reproductive organs, various glands, adipose tissue, skin, blood cells and neuronal tissues, especially in glial cells. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa, catalyzing the it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery.

Mechanism of action

The mechanism of action of entacapone is believed to be through its ability to inhibit COMT in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome.

TargetActionsOrganism
ACatechol O-methyltransferase
inhibitor
Humans
Absorption

Entacapone is rapidly absorbed (approximately 1 hour). The absolute bioavailability following oral administration is 35%.

Volume of distribution
  • 20 L
Protein binding

98% (bind to serum albumin)

Metabolism

Metabolized via isomerization to the cis-isomer, followed by direct glucuronidation of the parent and cis-isomer.

Route of elimination

Entacapone is almost completely metabolized prior to excretion, with only a very small amount (0.2% of dose) found unchanged in urine. As only about 10% of the entacapone dose is excreted in urine as parent compound and conjugated glucuronide, biliary excretion appears to be the major route of excretion of this drug.

Half-life

0.4-0.7 hour

Clearance
  • 850 mL/min
Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Side effect include increase the occurrence of orthostatic hypotension, severe rhabdomyolysis, dyskinesia, hallucinations, hyperkinesia, hypokinesia, dizziness, fatigu,e gastrointestinal effects including abdominal pain constipation diarrhea nausea

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Entacapone is combined with 1,2-Benzodiazepine.
AcebutololThe metabolism of Acebutolol can be decreased when combined with Entacapone.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Entacapone.
AcetazolamideThe risk or severity of CNS depression can be increased when Entacapone is combined with Acetazolamide.
AcetophenazineThe risk or severity of CNS depression can be increased when Entacapone is combined with Acetophenazine.
Food Interactions
  • Take with or without food. The absorption is unaffected by food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
International/Other Brands
Anxopone (Root) / Comtade (Novartis)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ComtanTablet, film coated200 mgOralOrion Corporation2016-09-082021-04-28EU flag
ComtanTablet, film coated200 mg/1OralCardinal Health2000-01-012013-06-30US flag
ComtanTablet, film coated200 mgOralOrion Corporation2020-12-16Not applicableEU flag
ComtanTablet, film coated200 mgOralOrion Corporation2016-09-082021-04-28EU flag
ComtanTablet200 mgOralSandoz Canada Incorporated2001-06-21Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-entacaponeTablet200 mgOralApotex CorporationNot applicableNot applicableCanada flag
Auro-entacaponeTablet200 mgOralAuro Pharma IncNot applicableNot applicableCanada flag
EntacaponeTablet, film coated200 mg/1OralAvKARE, Inc.2014-06-202018-09-17US flag
EntacaponeTablet, film coated200 mg/1OralMylan Institutional Inc.2013-12-122022-08-31US flag
EntacaponeTablet200 mg/1OralNCS HealthCare of KY, Inc dba Vangard Labs2017-06-06Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ANTIPAR 100 MG/ 25 MG/ 200 MG FİLM TABLET, 100 ADETEntacapone (200 mg) + Carbidopa hydrate (25 mg) + Levodopa (100 mg)Tablet, film coatedOralİLKO İLAÇ SAN.VE TİC. A.Ş.2017-08-11Not applicableTurkey flag
ANTIPAR 125 MG/ 31.25 MG/ 200 MG FİLM TABLET, 100 ADETEntacapone (200 mg) + Carbidopa hydrate (31.25 mg) + Levodopa (125 mg)Tablet, film coatedOralİLKO İLAÇ SAN.VE TİC. A.Ş.2017-08-11Not applicableTurkey flag
ANTİPAR 150 MG/37.5 MG/200 MG FİLM TABLET, 100 ADETEntacapone (200 mg) + Carbidopa hydrate (37.5 mg) + Levodopa (150 mg)Tablet, film coatedOralİLKO İLAÇ SAN.VE TİC. A.Ş.2017-07-26Not applicableTurkey flag
ANTIPAR 200 MG/50 MG/200 MG FILM TABLET, 100 ADETEntacapone (200 mg) + Carbidopa hydrate (50 mg) + Levodopa (200 mg)Tablet, film coatedOralİLKO İLAÇ SAN.VE TİC. A.Ş.2017-04-07Not applicableTurkey flag
ANTIPAR 50 MG/ 12.5 MG/ 200 MG FİLM TABLET, 100 ADETEntacapone (200 mg) + Carbidopa hydrate (12.5 mg) + Levodopa (50 mg)Tablet, film coatedOralİLKO İLAÇ SAN.VE TİC. A.Ş.2017-08-11Not applicableTurkey flag

Categories

ATC Codes
N04BX02 — Entacapone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hydroxycinnamic acids and derivatives. These are compounds containing an cinnamic acid (or a derivative thereof) where the benzene ring is hydroxylated.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Hydroxycinnamic acids and derivatives
Direct Parent
Hydroxycinnamic acids and derivatives
Alternative Parents
Nitrophenols / Nitrobenzenes / Nitroaromatic compounds / Catechols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Tertiary carboxylic acid amides / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Nitriles
show 5 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Allyl-type 1,3-dipolar organic compound / Aromatic homomonocyclic compound / Benzenoid / C-nitro compound / Carbonitrile / Carbonyl group / Carboxamide group / Carboxylic acid derivative
show 21 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid amide, catechols, nitrile (CHEBI:4798)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
4975G9NM6T
CAS number
130929-57-6
InChI Key
JRURYQJSLYLRLN-BJMVGYQFSA-N
InChI
InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
IUPAC Name
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
SMILES
CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N

References

Synthesis Reference

Pandurang Deshpande, Parven Luthra, Anand Pandey, Dharmesh Dhameliya, "Process for the preparation of (E)-2-cyano-3-(3, 4-dihydroxy-5-nitrophenyl)-N, N-diethyl-2-propenamide (entacapone)." U.S. Patent US20060258877, issued November 16, 2006.

US20060258877
General References
  1. Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. [Article]
  2. Chong BS, Mersfelder TL: Entacapone. Ann Pharmacother. 2000 Sep;34(9):1056-65. [Article]
  3. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. [Article]
  4. Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9. [Article]
  5. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [Article]
  6. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [Article]
  7. FDA Approved Drug Products: Comtan (entacapone) tablets for oral use [Link]
  8. FDA Approved Drug Products: Stalevo (carbidopa/levodopa/entacapone) tablets for oral use [Link]
Human Metabolome Database
HMDB0012226
KEGG Drug
D00781
KEGG Compound
C07943
PubChem Compound
5281081
PubChem Substance
46508734
ChemSpider
4444537
BindingDB
50108879
RxNav
60307
ChEBI
4798
ChEMBL
CHEMBL953
ZINC
ZINC000035342787
Therapeutic Targets Database
DAP000608
PharmGKB
PA164748726
PDBe Ligand
PD9
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Entacapone
PDB Entries
6ak4
FDA label
Download (52.6 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedTreatmentIdiopathic Parkinson's Disease1
4CompletedTreatmentParkinson's Disease (PD)6
4CompletedTreatmentParkinson's Disease With Wearing-off Motor Fluctuations1
4RecruitingTreatmentParkinson's Disease (PD)2
4TerminatedTreatmentParkinson's Disease (PD)1

Pharmacoeconomics

Manufacturers
  • Orion corp
Packagers
  • Cardinal Health
  • Dipharma
  • Kaiser Foundation Hospital
  • Neuland Laboratories Ltd.
  • Novartis AG
  • Orion Corporation
  • Resource Optimization and Innovation LLC
  • Vangard Labs Inc.
Dosage Forms
FormRouteStrength
Tablet, film coatedOral
TabletOral200 mg
TabletOral200.000 mg
Tablet, coatedOral200 mg
Tablet, film coatedOral200 MG
TabletOral200 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral
Tablet, coatedOral
TabletOral
Prices
Unit descriptionCostUnit
Comtan 200 mg tablet2.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5135950No1992-08-042010-10-31US flag
CA2342634No2008-01-292019-09-13Canada flag
CA1334967No1995-03-282012-03-28Canada flag
US6599530No2003-07-292018-09-14US flag
US6500867No2002-12-312020-06-29US flag
US6797732No2004-09-282020-06-29US flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0797 mg/mLALOGPS
logP2.5ALOGPS
logP1.63Chemaxon
logS-3.6ALOGPS
pKa (Strongest Acidic)6.09Chemaxon
pKa (Strongest Basic)-1.1Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area127.7 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity79.51 m3·mol-1Chemaxon
Polarizability29.55 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9185
Blood Brain Barrier-0.9104
Caco-2 permeable-0.5817
P-glycoprotein substrateSubstrate0.64
P-glycoprotein inhibitor INon-inhibitor0.7342
P-glycoprotein inhibitor IINon-inhibitor0.8442
Renal organic cation transporterNon-inhibitor0.9311
CYP450 2C9 substrateNon-substrate0.8406
CYP450 2D6 substrateNon-substrate0.8932
CYP450 3A4 substrateNon-substrate0.5057
CYP450 1A2 substrateNon-inhibitor0.7003
CYP450 2C9 inhibitorNon-inhibitor0.581
CYP450 2D6 inhibitorNon-inhibitor0.8548
CYP450 2C19 inhibitorNon-inhibitor0.6098
CYP450 3A4 inhibitorNon-inhibitor0.5133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7901
Ames testAMES toxic0.5803
CarcinogenicityNon-carcinogens0.561
BiodegradationNot ready biodegradable0.9457
Rat acute toxicity2.6750 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8608
hERG inhibition (predictor II)Non-inhibitor0.8332
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-003r-4190000000-da6b28638ec4920bd58a
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-0a4i-0329000000-8d20a5650e9c1b1c8275
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0329000000-8d20a5650e9c1b1c8275
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-190.9702839
predicted
DarkChem Lite v0.1.0
[M-H]-189.6311839
predicted
DarkChem Lite v0.1.0
[M-H]-163.07701
predicted
DeepCCS 1.0 (2019)
[M+H]+191.2344839
predicted
DarkChem Lite v0.1.0
[M+H]+189.3954839
predicted
DarkChem Lite v0.1.0
[M+H]+166.90434
predicted
DeepCCS 1.0 (2019)
[M+Na]+190.4853839
predicted
DarkChem Lite v0.1.0
[M+Na]+189.2751839
predicted
DarkChem Lite v0.1.0
[M+Na]+175.46965
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  2. Najib J: Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. [Article]
  3. Chong BS, Mersfelder TL: Entacapone. Ann Pharmacother. 2000 Sep;34(9):1056-65. [Article]
  4. Holm KJ, Spencer CM: Entacapone. A review of its use in Parkinson's disease. Drugs. 1999 Jul;58(1):159-77. [Article]
  5. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. [Article]
  6. Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9. [Article]
  7. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. [Article]
  8. Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama. 2002 Feb;56(1):1-6. [Article]
  9. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50. [Article]
  10. Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Lautala P, Ethell BT, Taskinen J, Burchell B: The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2000 Nov;28(11):1385-9. [Article]
  2. Kurkela M, Garcia-Horsman JA, Luukkanen L, Morsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, Finel M: Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem. 2003 Feb 7;278(6):3536-44. Epub 2002 Nov 14. [Article]
  3. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, Finel M: Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005 Jul;33(7):1017-26. Epub 2005 Mar 31. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55